Login to Your Account



Other News To Note


Wednesday, December 11, 2013

Daiichi Sankyo Co. Ltd., of Tokyo, reported results of a prespecified subgroup analysis of 771 cancer patients enrolled in the Phase III Hokusai-VTE study, showing that subjects with either a history of cancer or with active cancer treated with once-daily Factor Xa inhibitor edoxaban had a numerically lower incidence of recurrent symptomatic venous thromboembolism compared to warfarin (3.7 percent vs. 7.1 percent).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription